Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Antiplatelet Treatment with Dual Pathway Inhibition
Author(s): Tobias Geisler Added: 10 months ago

Anticoagulation

Prevention & Chronic Conditions
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19
Author(s): Andrea Di Lenarda , Nicola Ferri , Massimiliano Lanzafame , et al Added: 9 months ago

COVID-19

CV Disease in Special Populations
ESC 24: EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD
Author(s): Gi-Byoung Nam , Min Soo Cho Added: 8 months ago
ESC Congress 2024 — Edoxaban monotherapy significantly improves outcomes in high-risk patients with CAD and atrial fibrillation.Investigators, Dr Gi-Byoung Nam (Ulsan University Hospital, Ulsan, SK) and Dr Min Soo Cho (Asan Medical Center, Seoul, SK) join us to discuss the key findings from the EPIC-CAD trial (NCT03718559).This Korean multi-centre, open-labelled, randomised controlled study… View more

Anticoagulation

Electrophysiology & Arrhythmia
Prioritising Risk in CAD: A Patient-First Discussion on Antiplatelet Therapy
Author(s): Marco Valgimigli , Diana Gorog , Eliano Navarese , et al Added: 1 year ago
This on-demand version of the live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), demonstrates how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Key opinion leaders Prof Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese … View more

Anticoagulation
Prioritising Risk in CAD: A Patient-First Discussion on Antiplatelet Therapy
Author(s): Felicita Andreotti , Diana Gorog , Marco Valgimigli , et al Start date: Dec 14, 2023
This live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), will demonstrate how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Join key opinion leadersProf Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese (University of Sassari,… View more

Anticoagulation
Cardiovascular Effects of NSAIDs: A Review With a Focus on RA Patients
Author(s): Eirik Ikdahl , Anne Kerola , Eli Sollerud , et al Added: 5 months ago

Prevention & Chronic Conditions
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 10 months ago

Anticoagulation
Research Area(s) / Expertise: Job title: Associate Physician
Dr Michelle O’Donoghue, is an Associate Physician in the Cardiology Division of Brigham and Women’s Hospital, an Affiliate Physician in the Cardiology Division of Massachusetts General Hospital and an Assistant Professor in Medicine at Harvard Medical School in Boston, Massachusetts, US. She is an investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, founded by Dr Eugene… View more
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 1 month ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention
EuroPCR 24: The CAGEFREE II Trial
Author(s): Ling Tao Added: 1 year ago
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT… View more

Intervention